Your shopping cart is currently empty

JNJ4796 is an orally active fusion inhibitor of the influenza virus, inhibiting hemagglutinin (HA)-mediated fusion to neutralize the influenza A group 1 virus. JNJ4796 mimics the functionality of broadly neutralizing antibodies (bnAbs).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $2,120 | 8-10 weeks | 8-10 weeks | |
| 50 mg | $2,780 | 8-10 weeks | 8-10 weeks | |
| 100 mg | $3,700 | 8-10 weeks | 8-10 weeks |
| Description | JNJ4796 is an orally active fusion inhibitor of the influenza virus, inhibiting hemagglutinin (HA)-mediated fusion to neutralize the influenza A group 1 virus. JNJ4796 mimics the functionality of broadly neutralizing antibodies (bnAbs). |
| Targets&IC50 | H1/Bris:(EC50)12 nM, H5/Viet:3.24 μM(EC50), H1/Cal:66 nM(EC50), H1/PR8:22 nM(EC50), H1/SI06:13 nM(EC50), H5/H97:449 nM(EC50), H1/NCa:38 nM(EC50) |
| In vitro | The mechanism of action of JNJ4796 is demonstrated to be based on inhibition of the pH-sensitive conformational change of HA, like bnAb CR6261. That triggers the fusion of the viral and endosomal membranes and the release of the viral genome into the host cell[1]. |
| In vivo | JNJ4796(50 and 10 mg/kg; twice daily) treatment, initiated one day before the challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved. JNJ4796 (p.o.) protects mice from lethal challenge of 25 times the median lethal dose (LD50) of H1N1 A/Puerto Rico/8/1934 virus. Oral doses of JNJ4796 cause dose-dependent efficacy after a sublethal viral challenge (LD90), with twice-daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival[1]. |
| Molecular Weight | 537.57 |
| Formula | C28H27N9O3 |
| Cas No. | 2241664-16-2 |
| Smiles | CC(=O)Nc1ccc2oc(nc2c1)-c1ccnc(c1)C(=O)N1CCN(CC1)[C@@H](c1nnn(C)n1)c1ccccc1 |
| Relative Density. | 1.44 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.